Concepedia

Author

John A. Blessing

Gynecologic Oncology Group

Also Known As

J A Blessing, J BLESSING, J Blessing, J. A. Blessing, J. Blessing, J.A. BLESSING, J.A. Blessing, JOHN A. BLESSING, John A Blessing, John A. Blessing

301

Publications

17.6K

Citations

70

H-Index

51

Concepts

All Affiliations

Gynecologic Oncology GroupRoswell Park Comprehensive Cancer CenterIndiana University – Purdue University IndianapolisWake Forest UniversityUniversity of Mississippi
JA

About

John A. Blessing is an author at Gynecologic Oncology Group specializing in obstetrics, medicine, and gynecology oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

60

145

11.2K

2

Obstetrics

60

142

11.1K

3

Public Health

14

17

2.1K

4

Health Sciences

3

3

539

5

Immunology

1

1

35

John A. Blessing

×

196

Publications

16.8K

Citations

69

H-Index

YearCitations

Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

Francis J. Major, John A. Blessing, Steven G. Silverberg,

Cancer

1993

663

Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

David H. Moore, John A. Blessing, Richard P. McQuellon,

Journal of Clinical Oncology

2004

634

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Philip Bonomi, John A. Blessing, Frederick B. Stehman,

Journal of Clinical Oncology

1985

404

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

Peter G. Rose, John A. Blessing, Andrew R. Mayer,

Journal of Clinical Oncology

1998

402

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

G A Omura, John A. Blessing, Francis J. Major,

Journal of Clinical Oncology

1985

393

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

J.T. Thigpen, John A. Blessing, Harrison Ball,

Journal of Clinical Oncology

1994

389

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Martee L. Hensley, John A. Blessing, Koen DeGeest,

Gynecologic Oncology

2008

362

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

G Omura, Francis J. Major, John A. Blessing,

Cancer

1983

357

Results and complications of operative staging in cervical cancer: Experience of the Gynecologic Oncology Group

Leo D. Lagasse, William T. Creasman, Hugh M. Shingleton,

Gynecologic Oncology

1980

317

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Martee L. Hensley, John A. Blessing, Robert S. Mannel,

Gynecologic Oncology

2008

303

Page 1